Rapid advancements in several key aspects of newborn screening (NBS) have combined to enhance awareness and investment in NBS: an increasing understanding of the contribution of genetics to diseases of childhood, the development of novel therapies, the creation of technologies applicable to dried bloodspots and other mechanisms for efficient screening, and heightened public enthusiasm for the health-preserving benefits of NBS in children with identifiable and treatable conditions.
In the United States, NBS programs are the responsibility of the individual states, which determine those conditions to include in its own NBS panel. This individual approach by the states has been responsible for the significant variability in the numbers and types of conditions that are included in the NBS panels. 1 No federal entity has the authority to mandate that states will screen for, and manage, certain conditions. The Advisory Committee on Heritable Disorders and Genetic Diseases in Newborns and Children (Committee, Appendix A) was chartered in February 2003 to advise the Secretary of the federal Department of Health and Human Services in many areas surrounding heritable conditions in children, and specifically in the area of NBS. 2 The Committee is directed to review and report regularly on newborn and childhood screening practices for heritable disorders, to recommend improvements in the national newborn and childhood heritable screening programs, and to engage in the following activities:
1. Provide advice and recommendations to the Secretary concerning grants and projects awarded or funded under the designated authorizing Public Health Service (PHS) Act; 2. Provide technical information to the Secretary for the development of policies and priorities for the administration of grants under the designated PHS act; and 3. Provide such recommendations, advice or information as may be necessary to enhance, expand or improve the ability of the Secretary to reduce the mortality or morbidity in newborns and children from heritable disorders.
Early discussions of the Committee focused on the recommendations from a NBS expert panel convened by the American College of Medical Genetics (ACMG) at the request of the Health Resources and Services Administration (HRSA). The recommendations from the ACMG expert panel received considerable support from the public, medical, and affiliated pro-fessional organizations, though some dissenting opinions were expressed (Ref. 3, for example) . The Committee also endorsed this report and its recommendations in September 2005. 2 Subsequently, the ACMG report was published, 4 and a majority of states expanded their screening panels to include many, if not all, of the recommended conditions. 5 Although the number of screened conditions expanded, many other conditions were not included because of lack of information about the condition and its natural history, proven therapies, and/or a technology to detect the condition on a population-wide scale. To facilitate the inclusion of emerging evidence and novel technologies, the Committee, with input from key stakeholders, outlined a process for nomination and evidence review. In prospectively determining the process that will be used for the "nomination" of conditions to be considered for NBS, a critical area of discussion focused on how evidence supporting such a nomination is gathered, and importantly how the evidence is evaluated. It has been the consensus of the Committee that an independent scientific body will be established to evaluate the evidence related to adding conditions to the uniform panel. This body will then refer its objective assessment to the full Committee for review, recommendations, and management.
A key issue in the evaluation of evidence for NBS is that virtually all the conditions considered for screening pose serious health risks to those affected and are present at very low frequencies in the general pediatric population in the United States. Therefore, even when data suggest that health benefits for these rare conditions result from early recognition and treatment, the evidence is most likely not derived from a randomized control trial (RCT) even though a RCT is the most accepted type of evaluation used to judge treatment effectiveness. Furthermore, some of the evidence for treatment efficacy resides not in the peer-reviewed published literature but is proprietary and/or in the domain of the Food and Drug Administration. Therefore, new ground rules for weighing evidence will be needed to assess the validity of claims for health benefits to justify NBS for each disorder.
This report describes the formulation of that new process to nominate and review conditions for the recommended universal panel. The Committee agreed on the following fundamental principles for the nomination and review process of conditions: (1) The deliberative process will be rigorously evidence-based, even for relatively rare conditions; (2) The procedures for the creation of a deliberative system and the system itself will be transparent and accessible to the scientific and lay public; (3) The process will be consistent across the different phases of the review process and applied to all of the proposed conditions (http://mchb.hrsa.gov/ programs/genetics/committee/).
THE NOMINATION PROCESS
The Committee chair, Dr. R. Rodney Howell, appointed a Criteria Work Group to develop a system for consideration of new conditions and regularly report to the Committee. This work group was comprised of members of the Committee (voting and nonvoting members, see Appendix A), and had HRSA administrative support.
The Criteria Work Group proposed a Nomination Form (available online only; also available at: ftp://ftp.hrsa.gov/mchb/ genetics/NominationForm.pdf) and an overall process for the nomination and evidence review process by the Committee. Submission of the Nomination Form would initiate the consideration of any new condition as the first of a three-step approach (Fig. 1) . The second step would be an administrative review of the Nomination Form led by HRSA to ensure that the Form conformed to expectations for completeness. Then the Committee would review the Nomination Form to determine whether the nomination should go to formal scientific review or deferral of review until additional information could be provided by the nominator.
The proposed Nomination Form conformed to the general structure of the survey instrument used by ACMG to solicit expert input for the NBS report, 4 requiring information on three main aspects: the condition, the screening and diagnostic tests, and the treatment(s). In the presumed dearth of formal randomized controlled studies of screening, pilot screening data would be an essential element of the evidence to be considered in the nomination process. The Nomination Form also required citation of key supporting references, preferably from the scientific literature, but including expert opinion. Moreover, the points of focus for the Nomination Form needed to be consistent with all subsequent deliberative review for any condition. The Form was subsequently piloted for use by a number of medical experts and advocacy groups with a variety of conditions. Based on the results of that pilot, and public input, the Committee revised the Nomination Form and subsequently approved of its use. A single caveat was that until the entire review process was described and codified, the final Form could still undergo modification to assure consistency of evaluation throughout the review process. 
FORMAL SCIENTIFIC REVIEW
The third and most complex phase of the new process, formal scientific review, was envisioned by the Criteria Work Group as a multiphased process outlined in the algorithm (Fig.  1) . The fulcrum of scientific deliberation is an evidence-based review (EBR), developed by an Evidence Review Work Group (Evidence Workgroup) and described below. Engagement of the Evidence Workgroup will be triggered by the Committee for those nominated conditions considered to be ready for consideration (see algorithm) and will function semi-independently from the Committee, with two Committee members serving as liaison to the EBR on a rotating basis. EBR will occur through a structured process that conforms to national standards for EBR, 6 while accommodating the paucity of data on clinical outcomes for rare genetic disorders. The evidence review will include the strength of data supporting screening, diagnosis, and treatment for a particular condition. The Evidence Workgroup will present its analysis and findings to the Committee. The report to the Committee will consist of a presentation of findings, rather than specific recommendations for inclusion or exclusion in NBS.
Subsequently, the Committee deliberations and recommendations will be published and presented to the HHS Secretary, taking into consideration the findings of the Evidence Workgroup, as well as consideration about cost and value of screening. Recommendations could range from addition of new conditions, rejection, and identification of areas where more research is needed, such as the performance characteristics of the screening test (sensitivity and specificity) and the efficacy of treatment on averting the adverse outcomes of the disorder. This process was accepted by the Committee. 2 
THE NOMINATION FORM
The Nomination Form requires a description of the qualifications and background of the person(s) submitting the nomination, and a number of key characteristics defining the condition, testing, and treatment (available online only), accompanied by supporting references. The technical expertise required by the Nomination Form to produce an informative and acceptable nomination may demand coordinated input from experts in medical genetics, pediatric, and other specialty practitioners, researchers in specific conditions and tests, and parents caring for affected children, as well as disease-specific parent groups and/or from an umbrella group such as the Genetic Alliance. 7 Specific descriptions are required within the category of the condition: a succinct definition of the exact condition under consideration; the estimated incidence within the general newborn population; the type, timing, and degree of health threats to the newborn and/or child; its clinical spectrum of signs and symptoms. These data preferably will be derived from population-based pilot screening endeavors, although the Committee recognizes that this is not possible in all cases.
The section of the Nomination Form pertaining to the screening and diagnostic tests requires data on: sensitivity; specificity; clinical utility (estimated rates of false negatives and false positives); whether the screening test can be done on a Guthrie dried bloodspot card or requires additional approaches and/or technologies; if the appropriate timing of testing comports with that normally obtained through current screening procedures (i.e., first 1-2 weeks of life); if screening identifies or suggests the presence of conditions other than the targeted condition; definitive diagnostic testing also requires data about its reliability and availability.
The section on Treatment requires the provision of data on a description of current therapy(ies) and the extent to which they ameliorate the medical impact of the condition; the urgency of treatment on averting disease sequelae; potential risks of and barriers to treatment; and the availability of treatment for affected children.
A limited number of key references will be required for statements and data cited on the Nomination Form. Lastly, clear and complete statement from the nominator(s) of potential conflicts-of-interest declarations will be required.
EVIDENCE-BASED REVIEW
Under contract from HRSA, an Evidence Workgroup will be established for three purposes:
1. Initially propose definitions for the terms used in the Nomination Form; 2. Delineate an evidence revaluation process based on the principles of evidence-based review. The analytic framework will include specifying the processes for gathering and weighing the evidence, defining the criteria for inclusion and exclusion, and evaluating the quality of studies and the strength of the body of evidence. A protocol will be developed for systematic scientific literature search and analysis, as well as a model of the summary evidence tables to be used to present the Evidence Workgroup's data and findings for each review; 3. Conduct systematic reviews and syntheses of evidence for conditions as requested by the Committee.
The Evidence Workgroup will possess core expertise in general pediatrics, genetics, public health, epidemiology and evidence-based review methodology, and a consumer (parent of a child with a heritable disorder). Two members of the Committee also will serve on a rotating basis as nonvoting liaisons to the Evidence Workgroup.
In addition, the Evidence Workgroup will provide guidance to the Committee on determining a framework for assessing the relative costs involved in NBS and treatment for children diagnosed and treated early in life versus those detected by natural history and presenting complications. Other areas of interest for which the Evidence Workgroup will provide guidance are in managing conflict of interest within the Committee and the evidence review process. Additional input on the work of the Evidence Workgroup will be provided by an external expert review group, which Advancing the NBS panel will be recommended by the leader of the Evidence Workgroup and approved by the Chair of the Committee.
NEXT STEPS
The nomination process began in June 2007, as the Nomination Form and cover letter are available on the HRSA Website (http://mchb.hrsa.gov/programs/genetics/committee/ default.htm) for electronic or paper submission. Administrative review is underway, and completed forms will be forwarded to the Committee. Once the Evidence Workgroup and its structure for EBR has been reviewed and endorsed by the Committee, the committee will begin its deliberations and begin forwarding nominated conditions for EBR or returning them for further information. After the EBR is presented to the Committee, it will formulate a recommendation to the HHS Secretary. Those recommendations will be to add the condition to the uniform NBS panel or not, as well as to formulate any additional research questions that would address the appropriateness of screening and/or treatment for that condition. If a condition is not ready for national implementation, the Committee can recommend that pilot studies be conducted to gather further information about the condition, the tests, or treatment. In the early phases of this process, the Committee will solicit public input to continue to inform its work around recommendations via the regular Committee meetings and related processes. The first full review should be completed by mid-2008. Health professionals and consumers are now encouraged to submit collaboratively prepared nominations.
Following addition of any new condition(s) into the uniform panel, an evaluative process will be put in place to assess the impact of these additions on the quality and cost of expanded screening on state NBS programs. The screening community, parents, and pediatric providers will need to provide the essential data for that evaluation, the scope and method of which will need to be determined at or before implementation of expanded screening.
The impact of NBS on the health of the nation's newborns and children is vast, affecting the more than four million infants born annually in the United States, and potentially influencing screening programs abroad. Our ability to expand screening based on our rapidly advancing knowledge and increasing advancements in technology create the need for a careful and transparent process that builds consensus from the varied professional and lay communities engaged in NBS and policy development.
APPENDIX A
Members of the advisory committee on heritable disorders and genetic disease in newborns and children Lane, Room 18-05, Rockville, MD 20857, Phone: (301) 443-2170, Fax: (301) 443-1797. 
